← Back to Search

GLP-1 Receptor Agonist

Retatrutide for Type 2 Diabetes

Phase 3
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52
Awards & highlights

Summary

"This trial will test if retatrutide is better than a placebo for treating Type 2 Diabetes in people with kidney problems. Participants will be those who have not been able to control their blood sugar

Who is the study for?
This trial is for adults with Type 2 Diabetes who have moderate or severe kidney problems and whose blood sugar isn't well-controlled by long-acting insulin, possibly combined with metformin or SGLT2 inhibitors. Participants will be involved in the study for about 14 months and may need to attend up to 22 visits.Check my eligibility
What is being tested?
The trial is testing Retatrutide against a placebo to see if it's better at controlling blood sugar levels in people with Type 2 Diabetes who also have kidney issues. The participants' responses to these treatments are compared over time.See study design
What are the potential side effects?
While specific side effects of Retatrutide aren't listed here, common ones for diabetes medications can include low blood sugar, nausea, digestive issues, possible allergic reactions, and skin irritation at injection sites.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Secondary outcome measures
Change from Baseline in Body Weight
Change from Baseline in Fasting Serum Glucose
Change from Baseline in Systolic Blood Pressure (SBP)
+10 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Retatrutide Dose 3Experimental Treatment1 Intervention
Participants will receive retatrutide administered SC.
Group II: Retatrutide Dose 2Experimental Treatment1 Intervention
Participants will receive retatrutide administered SC.
Group III: Retatrutide Dose 1Experimental Treatment1 Intervention
Participants will receive retatrutide administered subcutaneously (SC).
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive placebo administered SC.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,629 Previous Clinical Trials
3,217,790 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,351 Previous Clinical Trials
416,156 Total Patients Enrolled
~213 spots leftby Sep 2026